A personalised cancer vaccine has shown encouraging results in a major clinical trial, reducing the risk of melanoma returning or causing death when used alongside standard immunotherapy. The findings could represent an important step towards more individualised cancer treatment.
The Phase 3 trial involved 1,137 patients with high-risk melanoma whose tumours had been surgically removed. Researchers tested whether adding a customised messenger RNA (mRNA) vaccine to the immunotherapy drug pembrolizumab could help prevent the disease from returning.
The results showed that patients receiving the combined treatment had a 42% lower relative risk of melanoma recurrence or death than those treated with pembrolizumab alone.
How the Personalised Cancer Vaccine Works
Unlike conventional vaccines designed to protect against infectious diseases, this treatment is developed using genetic information from an individual patient’s tumour.
Scientists analyse the tumour to identify specific mutations that can help the immune system distinguish cancer cells from healthy cells. The personalised mRNA vaccine then provides instructions that help the immune system recognise and target cells carrying those tumour-specific features.
The vaccine, known as intismeran autogene, was developed by Moderna and Merck. It is administered alongside pembrolizumab, an immunotherapy medicine that helps the immune system attack cancer cells.
The approach aims to strengthen the body’s ability to identify and fight cancer cells that may remain after surgery.
Trial Results Show Improved Recurrence-Free Outcomes
The study compared patients who received the personalised vaccine alongside pembrolizumab with those who received pembrolizumab and a placebo.
After approximately two years, 82.2% of patients in the combination-treatment group remained free of recurrence, compared with 70% in the group receiving pembrolizumab alone.
The combination also reduced the relative risk of distant cancer spread or death by 38%, according to the reported findings.
These results suggest that tailoring treatment to the genetic characteristics of a patient’s tumour may improve outcomes for certain people with high-risk melanoma. However, researchers will need longer follow-up to determine whether the improvement in recurrence-free outcomes translates into a clear long-term survival benefit.
What the Findings Mean for Patients
Melanoma is a serious form of skin cancer that can spread to other parts of the body. Surgery can remove a tumour, but some patients remain at risk of recurrence, making additional treatment important in appropriate cases.
A personalised vaccine could eventually offer another treatment option for selected patients after surgery. However, the results apply to the specific group studied and should not be interpreted as evidence that the vaccine works against every type of cancer.
The treatment remains investigational and is not yet approved for routine clinical use. Regulatory review, further follow-up and questions surrounding manufacturing costs and access will influence when it may become available to patients.
The findings offer encouraging evidence for personalised cancer medicine, while reinforcing the need for continued research before the treatment can become part of standard care.
